Aaron I. Davis
CIK 1465914 · last filed 2024-10-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNGX | Director | 6,799,435 | $23.53 | $159.99M | $5.59M | 8 | 2024-10-28 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | 4,815,754 | $10.15 | $48.88M | -$18.27M | 11 | 2024-06-13 |
| TYRA | 10%+ Owner | 6,534,298 | $19.34 | $126.37M | $43.00M | 3 | 2024-02-08 |
| RAIN | Director | 2,147,212 | $0.63 | $1.36M | $45.36M | 5 | 2024-01-26 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 1,572,368 | $58.70 | $92.30M | -$2.38M | 9 | 2024-01-23 |
| Odonate Therapeutics, Inc. (ODT) Delisted | Director | 5,232,842 | $1.12 | $5.86M | $44.99M | 9 | 2021-11-19 |
Recent Filings · Page 2 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-15 | TNGX | Buy (P) | +2,375,000 | $12.23M | EDGAR |
| 2023-08-11 | RAIN | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | TNGX | Grant (A) | +5,000 | $0 | EDGAR |
| 2023-02-13 | TYRA | Sell (S) | −531,136 | -$7.00M | EDGAR |
| 2023-01-24 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +4,444 | $0 | EDGAR |
| 2022-11-08 | RAIN | Buy (P) | +972,212 | $5.67M | EDGAR |
| 2022-10-13 | TNGX | Buy (P) | +1,185,000 | $5.22M | EDGAR |
| 2022-08-19 | RAIN | Grant (A) | — | $0 | EDGAR |
| 2022-06-28 | TNGX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.